BiotechTube
Biohaven

Biohaven

BHVNPhase 3
New Haven, United StatesFounded 2013200-500 employeesbiohaven.com

Biohaven is a neuroscience-focused biopharmaceutical company with a diversified portfolio of clinical-stage and commercial assets. Following the spin-off of its migraine franchise to Pfizer in 2022, the 'New Biohaven' is advancing a next-generation pipeline targeting neurodegenerative diseases, movement disorders, and neuropsychiatric conditions. The company leverages multiple scientific platforms, including its proprietary glutamate modulation and myostatin inhibition technologies, to address complex neurological disorders with significant market potential.

Market Cap
$1.3B
-70.7% period
Pipeline
37
16 in Phase 3
Patents
20
granted
Publications
19
indexed

BHVN · Stock Price

USD 8.7421.13 (-70.74%)

Historical price data

AI Company Overview

Biohaven is a neuroscience-focused biopharmaceutical company with a diversified portfolio of clinical-stage and commercial assets. Following the spin-off of its migraine franchise to Pfizer in 2022, the 'New Biohaven' is advancing a next-generation pipeline targeting neurodegenerative diseases, movement disorders, and neuropsychiatric conditions. The company leverages multiple scientific platforms, including its proprietary glutamate modulation and myostatin inhibition technologies, to address complex neurological disorders with significant market potential.

NeurologyNeuropsychiatryNeuromuscularOncology

Technology Platform

Biohaven leverages multiple neuroscience platforms: a glutamate modulation platform targeting NMDA, AMPA, and mGluR receptors; a myostatin inhibition platform for muscle disorders; and a Kv7 ion channel opener platform for neuronal hyperexcitability disorders.

Pipeline

37
37 drugs in pipeline16 in Phase 3
DrugIndicationStageWatch
Verdiperstat + PlaceboMultiple System AtrophyPhase 3
Troriluzole (BHV-4157)Obsessive Compulsive DisorderPhase 3
taldefgrobep alfa + Placebo + taldefgrobep alfaSpinal Muscular AtrophyPhase 3
Troriluzole + PlaceboObsessive-Compulsive DisorderPhase 3
Troriluzole + PlaceboGeneralized Anxiety DisorderPhase 3

Funding History

3
Total raised:$603M
PIPE$350MMar 15, 2021
IPO$173MMay 4, 2017
Series A$80MJun 15, 2016

Opportunities

Biohaven's primary growth opportunities lie in successfully advancing its Kv7 platform for epilepsy and anxiety disorders and its myostatin inhibitor for SMA and ALS.
Positive Phase 3 data in SMA could lead to a near-term regulatory filing and create a new standard of adjunctive care.
The company's strong cash position also allows for potential business development activities, including in-licensing or acquisitions to bolster its pipeline.

Risk Factors

Key risks include clinical trial failures across its pipeline, particularly for its lead assets BHV-7000 and taldefgrobep alfa.
The company also faces intense competition in all its target indications from larger, more established pharmaceutical companies.
Regulatory hurdles and the challenge of successfully commercializing novel therapies in complex neurological markets present additional significant risks.

Competitive Landscape

Biohaven competes in crowded therapeutic areas. In epilepsy/anxiety, it faces large pharma and biotech competitors like Jazz Pharmaceuticals, Neurocrine Biosciences, and Sage Therapeutics. In SMA/ALS, it competes with Biogen, Novartis, Roche, and Ionis Pharmaceuticals. Its differentiation is based on novel mechanisms of action (Kv7, myostatin inhibition) that aim to provide efficacy and safety advantages over existing standards of care.